These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31602777)

  • 1. Bevacizumab prescribing practices for epithelial ovarian cancer in Australia.
    Burdett N; Kichenadasse G
    Intern Med J; 2019 Oct; 49(10):1334-1335. PubMed ID: 31602777
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer.
    Wang PH
    Taiwan J Obstet Gynecol; 2018 Oct; 57(5):623-624. PubMed ID: 30342639
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of bevacizumab on the costs of ovarian cancer treatment in routine clinical practice.
    Vuorinen RK; Luukkaala TH; Mäenpää JU
    Acta Oncol; 2020 Apr; 59(4):453-457. PubMed ID: 31920123
    [No Abstract]   [Full Text] [Related]  

  • 4. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
    Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Australian Ovarian Cancer Study Group ; Webb P;
    Gynecol Oncol; 2013 May; 129(2):310-7. PubMed ID: 23403164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When in the treatment continuum to use PARP inhibition in ovarian cancer.
    Mirza MR
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):84-86. PubMed ID: 33596189
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
    Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
    Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Psychotropic Drug Prescribing in the United States: 2014-2015.
    Greenblatt DJ; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 2018 Feb; 38(1):1-4. PubMed ID: 29215384
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer.
    Sun R; Huang B; Wei LJ
    J Clin Oncol; 2023 Apr; 41(10):1952-1953. PubMed ID: 36763910
    [No Abstract]   [Full Text] [Related]  

  • 9. Do advertisements in clinical software influence prescribing?
    Mansfield PR
    Med J Aust; 2008 Jan; 188(1):13-4. PubMed ID: 18205555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpreting and analysing practice prescribing data.
    Nicholls J
    Community Nurse; 2000 Jul; 6(6):39-42. PubMed ID: 12778649
    [No Abstract]   [Full Text] [Related]  

  • 11. Off-label drug use: the bevacizumab story.
    Stewart MW
    Mayo Clin Proc; 2013 Mar; 88(3):305. PubMed ID: 23489456
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibiotic resistance and prescribing practices.
    Gonzales R
    Hosp Pract (1995); 1998 Apr; 33(4):11-2. PubMed ID: 9562826
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent changes in the profile of prescription NSAID use in Australia.
    McManus P; Henry DA; Birkett DJ
    Med J Aust; 2000 Feb; 172(4):188. PubMed ID: 10772594
    [No Abstract]   [Full Text] [Related]  

  • 14. A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study.
    Brett J; Elshaug AG; Bhatia RS; Chalmers K; Badgery-Parker T; Pearson SA
    Implement Sci; 2017 May; 12(1):58. PubMed ID: 28468629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin: prescribing practices and adverse events.
    Waldron DL; Bramble D; Gringras P
    Arch Dis Child; 2005 Nov; 90(11):1206-7. PubMed ID: 16243894
    [No Abstract]   [Full Text] [Related]  

  • 16. Counting the cost of critical antibiotic shortages.
    Khumra S; Mahony AA; Devchand M; Walker ST; Garrett K; Grayson ML; Trubiano JA
    J Antimicrob Chemother; 2019 Jan; 74(1):273-275. PubMed ID: 30307535
    [No Abstract]   [Full Text] [Related]  

  • 17. Abusive prescribing of controlled substances.
    Jha VM; Blum A
    N Engl J Med; 2013 Dec; 369(23):2269-70. PubMed ID: 24304063
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
    Zhang L; Zhou Q
    Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic prescribing rates in England are falling.
    Majeed A; Wrigley T
    BMJ; 2002 Aug; 325(7359):340. PubMed ID: 12169522
    [No Abstract]   [Full Text] [Related]  

  • 20. Electronic Prescriptions for Controlled Substances.
    Haddad PJ
    Mich Med; 2017 Mar; 116(2):10-11. PubMed ID: 30376251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.